Immunic, Inc. (IMUX)
IMUX moved a median of -0.42% 30 minutes after news, and -0.32% by the close. How IMUX actually reacts to news — the realized, point-in-time move the market made, measured across 305 labeled events over the last three years with zero look-ahead.
IMUX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 303 |
| 30-min | -0.42% | 42% | 303 |
| 60-min | -0.41% | 45% | 303 |
| to close | -0.32% | 47% | 299 |
| Middle 50% of IMUX reactions | -1.86% to +1.66% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 305 |
Half of all Immunic, Inc. news events land between -1.86% and +1.66% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMUX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.02% | 47% | 0.00% |
| Analyst downgrades | 11 | 0.00% | 46% | +0.82% |
| Coverage initiations | 32 | +0.30% | 53% | +1.20% |
| Rating reiterations | 64 | +0.14% | 52% | -1.68% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IMUX ranks against every other measured name →
That’s how IMUX usually reacts — get an email when it moves on news →Email me when IMUX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMUX's baseline. Nothing else.
Recent IMUX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immunic Appoints Jaa Roberson as Chief People Officer | Press release | PR Newswire | +1.86% | +0.29% | |
| Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.26% | -13.44% | |
| Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Press release | PR Newswire | -0.26% | -1.55% | |
| Form S-8 IMMUNIC, INC. | SEC filing · Form S-8 | SEC EDGAR | -0.23% | -8.40% | |
| Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.89% | +3.33% | |
| Form 8-K IMMUNIC, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | -1.75% | |
| Form 8-K IMMUNIC, INC. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | -4.17% | |
| Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Press release | PR Newswire | +1.33% | -3.13% | |
| Immunic Appoints Chitrang Davé as Chief Data and Digital Officer | Press release | PR Newswire | -0.22% | -9.16% | |
| Form S-8 IMMUNIC, INC. | SEC filing · Form S-8 | SEC EDGAR | -2.05% | +3.17% | |
| Form 10-Q IMMUNIC, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.28% | +8.78% | |
| Form 8-K IMMUNIC, INC. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.28% | +8.78% | |
| Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +2.28% | +8.78% | |
| Form 8-K IMMUNIC, INC. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +0.89% | |
| Immunic to Participate in Investor Conferences in July | Press release | PR Newswire | +0.20% | -1.07% | |
| Form 8-K IMMUNIC, INC. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | +3.23% | |
| Form 8-K IMMUNIC, INC. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | -1.66% | |
| Immunic to Participate in Investor, Industry and Scientific Conferences in June | Press release | PR Newswire | +0.16% | -2.66% | |
| Form DEF 14A IMMUNIC, INC. For: Jun 29 | SEC filing · Form DEF | SEC EDGAR | +0.60% | +1.14% | |
| Form 8-K IMMUNIC, INC. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +2.18% | +6.93% | |
| Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | Press release | PR Newswire | +2.18% | +6.93% | |
| Form 8-K IMMUNIC, INC. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +11.91% | |
| Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer | Press release | PR Newswire | +1.68% | +11.91% | |
| Form 8-K IMMUNIC, INC. For: May 16 | SEC filing · Form 8-K | SEC EDGAR | -2.55% | -1.44% | |
| Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | Press release | PR Newswire | -2.55% | -1.44% | |
| Form 10-Q IMMUNIC, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.26% | +12.51% | |
| Form 8-K IMMUNIC, INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +12.51% | |
| Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.26% | +12.51% | |
| Form EFFECT IMMUNIC, INC. | SEC filing · Form EFFECT | SEC EDGAR | +1.18% | +6.21% | |
| Form S-3/A IMMUNIC, INC. | SEC filing · Form S-3 | SEC EDGAR | +2.51% | +0.84% | |
| Immunic to Participate in Investor and Medical Conferences in May | Press release | PR Newswire | -4.43% | -5.22% | |
| Form 8-K IMMUNIC, INC. For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +12.21% | +12.21% | |
| Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer | Press release | PR Newswire | +12.21% | +12.21% | |
| Form 8-K IMMUNIC, INC. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | +3.18% | |
| Immunic, Inc. Announces 1-for-10 Reverse Stock Split | Press release | PR Newswire | +0.57% | +3.18% | |
| Form 10-K/A IMMUNIC, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.57% | +3.18% | |
| Form 8-K IMMUNIC, INC. For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +4.25% | +4.72% | |
| Form 8-K IMMUNIC, INC. For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +4.20% | +4.27% | |
| Form S-8 IMMUNIC, INC. | SEC filing · Form S-8 | SEC EDGAR | -8.40% | -10.69% | |
| Immunic to Participate in Scientific and Medical Conferences in April | Press release | PR Newswire | +0.42% | +8.40% | |
| Form S-3 IMMUNIC, INC. | SEC filing · Form S-3 | SEC EDGAR | +6.09% | +1.74% | |
| Form 8-K IMMUNIC, INC. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +2.43% | +1.77% | |
| Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | PR Newswire | +2.43% | +1.77% | |
| Form 8-K IMMUNIC, INC. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +3.74% | |
| Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton | Press release | PR Newswire | +0.47% | +3.74% | |
| Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium | Press release | PR Newswire | +4.69% | +0.78% | |
| Form D IMMUNIC, INC. | SEC filing · Form D | SEC EDGAR | +3.88% | -6.72% | |
| Immunic to Participate in Investor Conferences in March | Press release | PR Newswire | -0.47% | +0.94% | |
| Form DEF 14A IMMUNIC, INC. For: Apr 14 | SEC filing · Form DEF | SEC EDGAR | -0.47% | +0.94% | |
| Form 10-K IMMUNIC, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.60% | +2.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMUX section they belong to.
Where else IMUX is measured.
IMUX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immunic, Inc.'s median reaction calculated?
Every labeled IMUX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 305 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of IMUX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMUX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.